TY - JOUR AU - Woodward Mark AU - Mancia G. AU - Borghi C. AU - Manolis A. AU - Chalmers J. AB -

Chronic diseases afflict patients for many years, often to the end of life, and there is increasing need for estimating lifelong risk and for evaluating the effects of treatment in the long term. Yet recommendations for lifelong treatment are most frequently based on findings from randomized clinical trials lasting only a few years. There is therefore a clear need for much longer term data, and here we present the advantages and disadvantages of many strategies, including the use of long-term posttrial follow-up, of long-term prospective cohort studies, registry databases, and of administrative databases. We also emphasize the need for long-term cost-effectiveness studies. One of the most promising strategies comes from linkage of data gathered through the ever-expanding pool of administrative databases worldwide with data from other sources, including randomized trials and the many forms of observational study.

AD - aThe George Institute for Global Health, University of Sydney, Sydney, Australia bThe George Institute for Global Health, University of Oxford, Oxford, UK cDepartment of Epidemiology, Johns Hopkins University, Baltimore, Maryland, USA dDepartment of Medical and Surgical Sciences, University of Bologna, Bologna, Italy eDepartment of Cardiology, Asklepeion Hospital, Athens, Greece fUniversity of Milano-Bicocca gCentre of Epidemiology and Clinical Trials, IRCSS Istituto Auxologico Italiano, Milan, Italy. AN - 27270189 BT - Journal of Hypertension DP - NLM ET - 2016/06/09 LA - Eng LB - AUS
PROF
PDO
FY16 M1 - 8 N1 - Chalmers, John
Woodward, Mark
Borghi, Claudio
Manolis, Athanasios
Mancia, Giuseppe
J Hypertens. 2016 Jun 6. N2 -

Chronic diseases afflict patients for many years, often to the end of life, and there is increasing need for estimating lifelong risk and for evaluating the effects of treatment in the long term. Yet recommendations for lifelong treatment are most frequently based on findings from randomized clinical trials lasting only a few years. There is therefore a clear need for much longer term data, and here we present the advantages and disadvantages of many strategies, including the use of long-term posttrial follow-up, of long-term prospective cohort studies, registry databases, and of administrative databases. We also emphasize the need for long-term cost-effectiveness studies. One of the most promising strategies comes from linkage of data gathered through the ever-expanding pool of administrative databases worldwide with data from other sources, including randomized trials and the many forms of observational study.

PY - 2016 SN - 1473-5598 (Electronic)
0263-6352 (Linking) SP - 1473 EP - 9 T2 - Journal of Hypertension TI - Strategies to meet the need for long-term data VL - 34 Y2 - FY16 ER -